Report of Cases of COVID-19 in Patients Receiving Adalimumab Referred to the Rheumatology Clinics in Ahvaz City, Iran: Retrospective Cohort Study
Mehrdad Dargahi Malamir
1
(
)
Elham Rajaei
2
(
)
Anita Amrollahi
3
(
)
Saeed Hesam
4
(
)
Keywords: COVID, Adalimumab, Rheumatology, Cytokine Storm, Side Effects of Adalimumab, Rheumatic Diseases ,
Abstract :
This hypothesis has been proposed that the use of adalimumab in patients can prevent the damage caused by the cytokine storm in the patient's body. However, so far, there is not enough evidence regarding the role of the spread of COVID-19 in patients receiving adalimumab. In a cross-sectional study, 102 rheumatic patients sent to the rheumatology department for further assessment (Imam Khomeini and Golestan hospitals in Ahvaz from March 2018 until March 2021) who had taken adalimumab in the last six months to one year and were infected with COVID-19 were admitted. In this study, participants were assigned to two groups: the control group comprised rheumatic persons who did not receive adalimumab but had COVID-19, while the case group consisted of rheumatic patients with COVID-19 who were treated with adalimumab. The average age in the control and adalimumab groups was 43.11±6.43 and 39.90±11.08 years, respectively [P=0.09]. The duration of illness in the control and adalimumab groups was 7.8±6.69 and 6.45±4.56 years, respectively [P=0.08]. Positive PCR results were found in 47.1% of patients in the control and 52.9% in the adalimumab group [P=0.346]. CT scan results showed that 21.6% of patients in the control group and 29.4% in the adalimumab group exhibited pulmonary involvement, there was a statistically significant difference between the two groups. The length of hospitalization in the control and adalimumab groups was 3.07±1.27 and 2.9±1.3 days, respectively [P=0.976]. The difference in mortality between the two groups was not statistically significant [P=0.75]. Overall, these findings suggest that the use of adalimumab did not have an impact on the clinical improvement of patients with COVID-19.
1. Najafipour R., Mohammadi D., Momeni M., Moghbelinejad S., 2022. ACE-2 Expression and Methylation Pattern in Bronchoalveolar Lavage Fluid and Bloods of Iranian ARDS Covid-19 Patients. Int J Mol Cell Med. 11(1), 55-63.
2. Pellokila M. R., Nendissa D. R., Kapa M. M. J., Sui J. M., Elbaa E. F., Kana Y. R., Elim Y. V., Lerik C. M., 2023. Environmental challenges due to COVID-19: Implications of altered distribution patterns and rice price dynamics in surplus and deficit areas of Indonesia. Casp J Environ Sci. 21(5), 1159-1170. doi: 10.22124/cjes.2023.7406.
3. Soltani M., Abdi F., Shahsavari S., 2024. Exploring dermatological complications of drugs used in acute respiratory syndrome coronavirus 2 treatment: A mini review. J Biochem Phytomed. 3(1), 8-13. doi: 10.34172/jbp.2024.4.
4. Widoyo H., Mohammed Z. Y., Ramírez-Coronel A. A., Iswanto A. H., Thattarauthodiyil U., Alkhayyat A. S., Karimi M., Bahmani M., Eftekhari Z., 2023. Herbal therapy in Covid-19: A systematic review of medicinal plants effective against Covid-19. Casp J Environ Sci. 21(5), 1289-1298. doi: 10.22124/cjes.2023.7431.
5. Hassanzadeh Khanmiri H., Mohammad A. A., Yousif R. S., Jasim S. A., Kzar H. H., Lafta M. H., Jalil A. T., Romero Parra R. M., Darvishi M., 2023. SARS-CoV2 neuroinvasive potential in respiratory failure in COVID-19 patients. Casp J Environ Sci. 21(2), 467-472. doi: 10.22124/cjes.2023.6635.
6. Heryadi D. Y., Tannady H., Dwinoor Rembulan G., Rofatin B., Siti Sundari R., 2023. Changes in behavior and welfare of organic rice farmers during the COVID-19 pandemic. Casp J Environ Sci. 21(1), 191-197. doi: 10.22124/cjes.2023.6220.
7. Figueroa-Parra G., Aguirre-Garcia G. M., Gamboa-Alonso C. M., Camacho-Ortiz A., Galarza-Delgado D. A., 2020. Are my patients with rheumatic diseases at higher risk of COVID-19? Ann Rheum Dis. 79(6), 839-40.
8. Conway R., Grimshaw A. A., Konig M. F., Putman M., Duarte-García A., Tseng L. Y., et al., 2022. SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis. Arthritis Rheumatol. 74(5), 766-75.
9. Atzeni F., Masala I. F., Rodríguez-Carrio J., Ríos-Garcés R., Gerratana E., La Corte L., et al., 2021. The Rheumatology Drugs for COVID-19 Management: Which and When? J Clin Med. 10(4), 2.
10. Grainger R., Kim A. H. J., Conway R., Yazdany J., Robinson P. C., 2022. COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nat Rev Rheumatol. 18(4), 191-204.
11. Montazersaheb S., Hosseiniyan Khatibi S. M., Hejazi M. S., Tarhriz V., Farjami A., Ghasemian Sorbeni F., et al., 2022. COVID-19 infection: an overview on cytokine storm and related interventions. Virol J. 19(1), 92.
12. Brenner E.J., Ungaro R.C., Gearry R.B., Kaplan G.G., Kissous-Hunt M., Lewis J. D., et al., 2020. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterol. 159(2), 481-91.
13. Hansel T.T., Kropshofer H., Singer T., Mitchell J.A., George A. J.T., 2010. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 9(4), 325-38.
14. Feldmann M., Maini R. N., Woody J. N., Holgate S. T., Winter G., Rowland M., et al., 2020. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 395(10234), 1407-9.
15. Fakharian A., Barati S., Mohamadi M., Dastan F., 2022. Successful Management of COVID-19 With Adalimumab in a Post-Coronary Artery Bypass Graft Surgery Patient. J Cardiothorac Vasc Anesth. 36(4), 1115-7.
16. Fredi M., Cavazzana I., Moschetti L., Andreoli L., Franceschini F., 2020. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. Lancet Rheumatol 2(9), e549-e56.
17. Haberman R. H., Castillo R., Chen A., Yan D., Ramirez D., Sekar V., et al., 2020. COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes. Arthritis Rheumatol. 72(12), 1981-9.
18. Akiyama S., Hamdeh S., Micic D., Sakuraba A., 2021. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 80(3), 384-91.
19. Vakili S., Rostami A., Jahromi B. N., Jafarinia M., 2024. Changes in Inflammatory Cytokines, Vascular Markers, Cell Cycle Regulators, and Gonadotropin Receptors in Granulosa Cells of COVID-19 Infected Women: Gene Expression Analysis in Granulosa Cells of COVID-19 Infected Women. Galen Med J. 13, e3625.
20. Aleksandrovna Kormishkina L., Danilovich Kormishkin E., Koloskov D. A., 2022. Environmental investment, the main condition for the COVID-19 post-pandemic recovery of Russian economy and transition to sustainable economic growth. Casp J Environ Sci. 20(5), 1069-1082. doi: 10.22124/cjes.2022.6081.
21. Kamali M., Sadati A. K., Khademi M. R., Ghahramani S., Zarei L., Ghaemi S. Z., Lankarani K. B., 2020. Burnout among nurses during coronavirus disease 2019 outbreak in Shiraz. Galen Med J 9, e1956.
22. Vidyadhar K. G., Narenkumar K., Prabhakar K. A., 2024. Effects of First Wave of COVID-19 on Colon Cancer Multi-disciplinary Team Performance: A Two-Year Analysis. Galen Med J. 13, 1.
23. Karimi M., Gholami-Ahangaran M., 2021. A Brief Report on Current Evidence of Traditional Chinese Medicine in the Treatment of Patients Infected with SARS-CoV-2. Plant Biotechnol Persa. 3(1), 34-36.
24. Al-Awade H. A. R., 2022. Effect of smoking on infection with COVID-19. Casp J Environ Sci. 20(2), 407-411. doi: 10.22124/cjes.2022.5588.
25. Shoushtari M. H., Raji H., Borsi S. H., Tavakol H., Cheraghian B., Moeinpour M., 2024. Evaluating the Therapeutic Effect of Sofosbuvir in Outpatients with COVID-19: A Randomized Clinical Trial Study. Galen Med J. 13, 1.
26. Hatami A., Hajiloo A., Bayati R., Kakavand P., Nasrollahi A. H., Yarahmadi A. H., Asadi H., 2022. Public COVID-19 vaccination acceptance: A narrative review of correlated factors. Adv Life Sci. 9(2), 143-150.
